QUEBEC CITY, February 19, 2025--(BUSINESS WIRE)--Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD; OTCQB: ...

Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solution ...

Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on ...

QUEBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to ...

Thykamine™, the first pharmaceutical product issued from Devonian’s SUPREX™ platform, is a highly innovative product for the prevention and treatment of health conditions related to inflammation and ...

Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammatory diseases ...

Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammatory diseases ...

Fibrotic tissue pathologic buildup leads to a loss of structural integrity and function, which raises morbidity and mortality. Thykamine™, the first pharmaceutical product issued from Devonian’s ...

Devonian Health Group Inc. Mr. Luc Gregoire President & CEO Dr. Andre P. Boulet, PhD Chairman, Chief Scientific Officer Telephone: 1 (450) 979-2916 E-mail: [email protected] Renmark ...

QUEBEC CITY--(BUSINESS WIRE)-- Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to ...

Left untreated, MASH can ultimately progress to cirrhosis of the liver and hepatocellular carcinoma, liver failure and death. Thykamine™, the first pharmaceutical product issued from Devonian’s ...